Reserpine

This classification denotes a multidrug resistance modulator and adrenergic agent with the molecular formula C33H40N2O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8B1QWR724A, chemically known as 20alpha-yohimban-16beta-carboxylic acid, 18beta-hydroxy-11,17alpha-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester) (8ci) but generally known as reserpine, which bears US NIH Compound Identifier 5052. European Medicines Agency schedules Reserpine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10286MIG. The term RESERPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules reserpine in its Anatomical Therapeutic Chemical (ATC) Classification. RESERPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule reserpine under HS 29399900 and SITC 54149. As of Q4 2014, RESERPINE remains the US FDA Preferred Term for this commodity. Reserpine bears US NLM identifiers UMLS ID C0035179 and NCI Concept Code C803. SMILES: O(C1C(C2C(CN3C(C2)c2[nH]c4c(c2CC3)ccc(OC)c4)CC1OC(=O)c1cc(OC)c(OC)c(OC)c1)C(=O)OC)C.